Virginia is set to receive approximately $16.4 million from a nationwide settlement involving eight drug manufacturers accused of contributing to the opioid crisis. Attorney General Jason Miyares announced the settlements, totaling around $720 million.
The companies involved in the settlement include Mylan (now part of Viatris), Hikma, Amneal, Apotex, Indivior, Sun, Alvogen, and Zydus. These firms have agreed to pay various amounts over different timeframes as follows:
– Mylan: $284,447,916 over nine years
– Hikma: $95,818,293 over one to four years
– Amneal: $71,751,010 over 10 years
– Apotex: $63,682,369 in a single year
– Indivior: $38,022,450 over four years
– Sun: $30,992,087 over one to four years
– Alvogen: $18,680,162 in a single year
– Zydus: $14,859,220 in a single year
Most of these companies are now prohibited from promoting or marketing opioids and products containing more than 40 mg of oxycodone per pill. They must also implement systems for monitoring suspicious orders. Indivior has committed not to manufacture or sell opioid products for the next decade but can continue with medications treating opioid use disorder.
This settlement was reached through negotiations led by attorneys general from several states including Virginia’s Jason Miyares and those from California and New York among others.
